Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-month Prospective Observational Study Assessing the Real-world Clinical Effectiveness, Safety and Health-economic Benefits of Toujeo Initiation After Oral Antidiabetic Drug Failure in Insulin-naïve Patients With Type 2 Diabetes Mellitus

Next Previous
Search
Trial Profile

A 12-month Prospective Observational Study Assessing the Real-world Clinical Effectiveness, Safety and Health-economic Benefits of Toujeo Initiation After Oral Antidiabetic Drug Failure in Insulin-naïve Patients With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ATOS
  • Sponsors Sanofi

Most Recent Events

  • 27 Dec 2022 Results of sub-group analysis assessing real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in achieving glycaemic goals in insulin-naive people with type 2 diabetes (T2D) in Mexico, Colombia and Peru, published in the Diabetes, Obesity and Metabolism.
  • 23 Sep 2022 Results (n=3651) of post hoc analysis assessing the baseline factors and outcomes associated with different magnitudes of Gla-300titration in people initiating basal insulin presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
  • 07 Jun 2022 Results assessing changes in treatment satisfaction and health status among participants, presented at the 82nd Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top